Modality
Small Molecule
MOA
TROP-2 ADC
Target
EGFR
Pathway
Lipid Met
Breast Ca
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
→ Jan 2031
Phase 1Current
NCT04158706
1,245 pts·Breast Ca
2023-03→2031-01·Completed
NCT03498388
899 pts·Breast Ca
2020-05→2025-11·Completed
2,144 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-234mo agoInterim· Breast Ca
2031-01-284.8y awayInterim· Breast Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Complet…
P1
Complet…
Catalysts
Interim
2025-11-23 · 4mo ago
Breast Ca
Interim
2031-01-28 · 4.8y away
Breast Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04158706 | Phase 1 | Breast Ca | Completed | 1245 | ACR20 |
| NCT03498388 | Phase 1 | Breast Ca | Completed | 899 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR |